Literature DB >> 28185107

Protective impact of resveratrol in experimental rat model of hyperoxaluria.

Taylan Oksay1, Sedat Yunusoğlu2, Mustafa Calapoğlu3, I Aydın Candan4, İbrahim Onaran5, Osman Ergün6, Alper Özorak1.   

Abstract

PURPOSE: Resveratrol (RES) is a polyphenol with antioxidant, anti-inflammatory, and many other physiological effects on tissues. In the present study, the effect of resveratrol in hyperoxaluria driven nephrolithiasis/nephrocalcinosis is investigated.
METHODS: Wistar-Albino rats of 250-300 g (male, n = 24) were included in the present study. The rats were randomized into three groups: Group 1 consisted of the controls (n = 8), Group 2 of hyperoxaluria (1% ethylene glycol (EG), n = 8), and Group 3 of the treatment (1% EG + 10 mg/kg of RES, n = 8) group. At the beginning and fifth week of the study, two rats from each group were placed in metabolic cages for 24 h and their urine was collected. At the end of the study, the rats were killed and their blood was collected from the vena cava inferior. The right kidneys of the rats were used for biochemical and the left ones for immunohistochemical analyzes. Malondialdehyde (MDA), catalase, urea, calcium, oxalate, and creatinine clearance were studied in the blood, urine, and kidney tissues. Moreover, routine histological evaluation, and p38-MAPK and NFkB immunohistochemical analyses were conducted.
RESULTS: In the hyperoxaluria group, urinary oxalate levels were higher than the control group; yet, lower in the treatment group compared to hyperoxaluria group (p < 0.05). Serum MDA levels in the hyperoxaluria group were higher than the control group; but in the treatment group it is lower than the hyperoxaluria group (p < 0.05). P38 MAPK activity was higher in the hyperoxaluria group compared to the control (p < 0.05). However, in terms of p38 MAPK activity, there were no statistically significant difference between hyperoxaluria and the treatment group (p < 0.069). Whereas NFkB activity in the hyperoxaluria group is higher than the control (p < 0.001), no statistically significant difference was observed with the treatment group.
CONCLUSIONS: In the present study, resveratrol was seen to prevent hyperoxaluria. With preventing oxidative stress factors and Randall plaque formation caused by free oxygen radicals, resveratrol can be an alternative treatment option that can increase the success rate in preventing stone recurrence in the future.

Entities:  

Keywords:  Calcium oxalate; Ethylene glycol; Hyperoxaluria; Rat; Resveratrol

Mesh:

Substances:

Year:  2017        PMID: 28185107     DOI: 10.1007/s11255-017-1534-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  37 in total

Review 1.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.

Authors:  Sanjay Kumar; Jeffrey Boehm; John C Lee
Journal:  Nat Rev Drug Discov       Date:  2003-09       Impact factor: 84.694

Review 2.  Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms.

Authors:  Giovanni Gambaro; Giuseppe Vezzoli; Giorgio Casari; Luca Rampoldi; Angela D'Angelo; Loris Borghi
Journal:  Am J Kidney Dis       Date:  2004-12       Impact factor: 8.860

3.  Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis.

Authors:  Yasunori Itoh; Takahiro Yasui; Atsushi Okada; Keiichi Tozawa; Yutaro Hayashi; Kenjiro Kohri
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

4.  Protective role of aminoguanidine on gentamicin-induced acute renal failure in rats.

Authors:  Alaadin Polat; Hakan Parlakpinar; Seda Tasdemir; Cemil Colak; Nigar Vardi; Muharrem Ucar; Memet Hanifi Emre; Ahmet Acet
Journal:  Acta Histochem       Date:  2006-09-26       Impact factor: 2.479

Review 5.  Flavonoids: a review of probable mechanisms of action and potential applications.

Authors:  R J Nijveldt; E van Nood; D E van Hoorn; P G Boelens; K van Norren; P A van Leeuwen
Journal:  Am J Clin Nutr       Date:  2001-10       Impact factor: 7.045

6.  Tetramethylpyrazine protects rat renal tubular cell apoptosis induced by gentamicin.

Authors:  Shu-Hui Juan; Cheng-Hsien Chen; Yung-Ho Hsu; Chun-Cheng Hou; Tso-Hsiao Chen; Heng Lin; Yen-Ling Chu; Yuh-Mou Sue
Journal:  Nephrol Dial Transplant       Date:  2006-11-28       Impact factor: 5.992

Review 7.  The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer.

Authors:  E Middleton; C Kandaswami; T C Theoharides
Journal:  Pharmacol Rev       Date:  2000-12       Impact factor: 25.468

8.  Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones.

Authors:  Ho-Shiang Huang; Ming-Chieh Ma; Chau-Fong Chen; Jun Chen
Journal:  Urology       Date:  2003-12       Impact factor: 2.649

9.  Oxalate toxicity in LLC-PK1 cells: role of free radicals.

Authors:  C Scheid; H Koul; W A Hill; J Luber-Narod; L Kennington; T Honeyman; J Jonassen; M Menon
Journal:  Kidney Int       Date:  1996-02       Impact factor: 10.612

10.  Bergenin attenuates renal injury by reversing mitochondrial dysfunction in ethylene glycol induced hyperoxaluric rat model.

Authors:  Deepika Aggarwal; Diksha Gautam; Minu Sharma; S K Singla
Journal:  Eur J Pharmacol       Date:  2016-10-05       Impact factor: 4.432

View more
  2 in total

1.  Protective effect of pentoxifylline on oxidative renal cell injury associated with renal crystal formation in a hyperoxaluric rat model.

Authors:  Hayrettin Ozturk; Ayhan Cetinkaya; Tulin Siviloglu Firat; Buket Kin Tekce; Selma Erdogan Duzcu; Hulya Ozturk
Journal:  Urolithiasis       Date:  2018-07-06       Impact factor: 3.436

2.  Resveratrol Attenuates Oxalate-Induced Renal Oxidative Injury and Calcium Oxalate Crystal Deposition by Regulating TFEB-Induced Autophagy Pathway.

Authors:  Yue Wu; Yang Xun; Jiaqiao Zhang; Henglong Hu; Baolong Qin; Tao Wang; Shaogang Wang; Cong Li; Yuchao Lu
Journal:  Front Cell Dev Biol       Date:  2021-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.